Best Health Care Sector ETFs
Pharma, biotech, devices, and insurers
ETFs tracked
73
Avg TER
0.54%
Median CAGR 3Y
+5.2%
Healthcare sector ETFs hold pharmaceuticals, biotechnology, medical devices, managed care insurers, and healthcare services. XLV, the largest broad fund, concentrates its top 3 holdings (UnitedHealth, Eli Lilly, Johnson & Johnson) at around 27% of the fund. Narrower slices target specific sub-sectors: IBB for biotech, IHI for medical devices, PJP for pharma.
The sector is considered defensive. Healthcare demand is relatively inelastic: patients need drugs, insurance, and care regardless of the economic cycle, which makes earnings more stable than cyclical sectors. XLV's beta to the S&P 500 is around 0.75, and drawdowns during bear markets have typically been shallower than broad equity. In 2008 XLV fell 22% versus 38% for the S&P 500; in 2022 it fell 7% versus 19%.
Sub-sector composition matters a lot. Biotech (IBB, XBI) is the most speculative slice — small-cap biotech prices swing wildly on trial data and FDA decisions. Pharma (PJP) is mature, dividend-paying, and less volatile. Medical devices (IHI) sit between the two. Managed care (UnitedHealth, Humana, Anthem) is more sensitive to regulatory risk, particularly around Medicare Advantage rate decisions and policy changes. Within the broad XLV, managed care is roughly 20% weight.
Dividend yields are modest. XLV yields around 1.5%, PJP around 2%, and managed-care-heavy funds slightly higher. The sector is not primarily an income play. Its appeal is stable-growth earnings power over long cycles. US healthcare represents about 18% of GDP and has grown as a share of the economy for decades. Sector ETFs benefit from this secular trend while adding GLP-1 obesity drugs, oncology pipelines, and AI-assisted diagnostics as more recent growth drivers.
Who this is for
- Investors wanting defensive sector exposure with stable earnings growth
- Long-horizon portfolios tilting toward demographic tailwinds
- Not suitable for speculative biotech exposure — use dedicated biotech ETFs instead
Top 10 ETFs
Browse all 73 health care ETFs
Filter, sort, and compare in the Beacon screener
Open screenerFrequently asked questions
- What is in a healthcare sector ETF?
- Broad healthcare ETFs (XLV, VHT) hold pharmaceuticals (Lilly, Pfizer, Merck), biotechnology (Amgen, Gilead), medical devices (Medtronic, Abbott), managed care (UnitedHealth, Humana), and healthcare services. Sub-sector funds target individual categories — IBB or XBI for biotech, IHI for devices, PJP for pharma.
- Is healthcare cyclical or defensive?
- Defensive. Healthcare demand is relatively inelastic to economic conditions, which makes sector earnings more stable than cyclical industries like materials or industrials. Healthcare ETFs have historically drawn down less than the broad market during recessions — XLV fell 22% in 2008 vs 38% for the S&P 500.
- Should I pick XLV or IBB for healthcare exposure?
- Different products. XLV is broad and diversified across pharma, devices, and managed care. IBB is concentrated biotech only. Biotech is structurally more speculative — XBI and IBB have experienced drawdowns of 40%+ during pipeline setbacks. Most investors use XLV or VHT as the core, adding biotech as a smaller tactical position if desired.
- How much regulatory risk is in a healthcare ETF?
- Managed care sub-sector is most exposed — Medicare Advantage rate changes and policy reforms affect earnings directly. Pharma faces drug-pricing legislation risk. Broad ETFs diversify this risk but don't eliminate it. The Inflation Reduction Act's Medicare drug-price negotiation provisions are an active example affecting major pharma holdings.
Related Sector